SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer

BACKGROUND: Some patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) respond poorly to anti-programmed cell death protein 1 (PD-1)/anti-programmed death-ligand 1 (PD-L1) treatments. Combination with other agents may improve the outcomes. This open-label, multicenter, phase 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jun, Yu, Xinmin, Huang, Dingzhi, Ma, Zhiyong, Gao, Bo, Cui, Jiuwei, Chu, Qian, Zhou, Qing, Sun, Meili, Day, Daphne, Wu, Jingxun, Pan, Hongming, Wang, Lifeng, Voskoboynik, Mark, Wang, Zhehai, Liu, Yunpeng, Li, Hui, Zhang, Juan, Peng, Yanyan, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944269/
https://www.ncbi.nlm.nih.gov/pubmed/36808075
http://dx.doi.org/10.1136/jitc-2022-006055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944269/
https://www.ncbi.nlm.nih.gov/pubmed/36808075
http://dx.doi.org/10.1136/jitc-2022-006055

Ejemplares similares